ES2929133T3 - Composiciones y métodos para la absorción transmucosa - Google Patents

Composiciones y métodos para la absorción transmucosa

Info

Publication number
ES2929133T3
ES2929133T3 ES13804115T ES13804115T ES2929133T3 ES 2929133 T3 ES2929133 T3 ES 2929133T3 ES 13804115 T ES13804115 T ES 13804115T ES 13804115 T ES13804115 T ES 13804115T ES 2929133 T3 ES2929133 T3 ES 2929133T3
Authority
ES
Spain
Prior art keywords
equal
cyclobenzaprine
administration
hours
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13804115T
Other languages
English (en)
Spanish (es)
Inventor
Harry Brittain
Seth Lederman
Giorgio Reiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tonix Pharma Holdings Ltd
Original Assignee
Tonix Pharma Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tonix Pharma Holdings Ltd filed Critical Tonix Pharma Holdings Ltd
Application granted granted Critical
Publication of ES2929133T3 publication Critical patent/ES2929133T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
ES13804115T 2012-06-15 2013-06-14 Composiciones y métodos para la absorción transmucosa Active ES2929133T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261660593P 2012-06-15 2012-06-15
US201261667774P 2012-07-03 2012-07-03
US201261725402P 2012-11-12 2012-11-12
US201361792900P 2013-03-15 2013-03-15
PCT/US2013/046023 WO2013188847A1 (en) 2012-06-15 2013-06-14 Compositions and methods for transmucosal absorption

Publications (1)

Publication Number Publication Date
ES2929133T3 true ES2929133T3 (es) 2022-11-25

Family

ID=49758769

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13804115T Active ES2929133T3 (es) 2012-06-15 2013-06-14 Composiciones y métodos para la absorción transmucosa

Country Status (26)

Country Link
US (1) US20140171515A1 (ja)
EP (1) EP2861223B1 (ja)
JP (5) JP6259452B2 (ja)
CN (2) CN104684550A (ja)
AR (1) AR092330A1 (ja)
AU (2) AU2013274003B2 (ja)
BR (1) BR112014031394B1 (ja)
CA (2) CA3118913C (ja)
DK (1) DK2861223T3 (ja)
ES (1) ES2929133T3 (ja)
HK (1) HK1209361A1 (ja)
HR (1) HRP20221325T1 (ja)
HU (1) HUE060175T2 (ja)
IL (1) IL236268B (ja)
LT (1) LT2861223T (ja)
MX (2) MX2014015436A (ja)
MY (1) MY194495A (ja)
NZ (2) NZ726488A (ja)
PL (1) PL2861223T3 (ja)
PT (1) PT2861223T (ja)
RS (1) RS63822B1 (ja)
SG (2) SG11201408318RA (ja)
SI (1) SI2861223T1 (ja)
TW (3) TWI642429B (ja)
WO (1) WO2013188847A1 (ja)
ZA (1) ZA201500288B (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2501234T (lt) 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
PT2968992T (pt) 2013-03-15 2020-02-18 Tonix Pharma Holdings Ltd Formulações eutécticas de cloridrato de ciclobenzaprina e manitol
MX2017003644A (es) * 2014-09-18 2017-10-31 Tonix Pharma Holdings Ltd Formulaciones eutecticas de clorhidrato de ciclobenzaprina.
AU2016293117B2 (en) * 2015-07-15 2021-04-15 Theranexus Use of amitriptyline for blocking brain hemichannels and method for potentiating its effect in vivo
US20190247296A1 (en) * 2016-09-02 2019-08-15 Nova Southeastern University Atropine sulfate rapidly-disintegrating sublingual tablets of improved formulation, methods for manufacture thereof, and methods for use thereof for treatment of acute organophosphate toxicity
CA3069699A1 (en) * 2017-07-13 2019-01-17 Tonix Pharmaceuticals Holding Corp. Analogs of cyclobenzaprine and amitryptilene
CN107519142B (zh) * 2017-08-24 2021-02-26 正大制药（青岛）有限公司 一种盐酸环苯扎林舌下片及其制备方法
CN107496355B (zh) * 2017-08-24 2021-04-30 正大制药（青岛）有限公司 一种盐酸环苯扎林舌下喷雾剂及其制备方法
WO2019110723A1 (en) * 2017-12-08 2019-06-13 F. Hoffmann-La Roche Ag Pharmaceutical formulation
US11826321B2 (en) 2017-12-11 2023-11-28 Tonix Pharma Holdings Limited Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN108721240A (zh) * 2018-06-08 2018-11-02 华益药业科技(安徽)有限公司 一种25mg阿米替林薄膜包衣片处方和工艺规程
TW202019400A (zh) 2018-08-20 2020-06-01 愛爾蘭商托尼克製藥控股有限公司 治療急性壓力症候群及創傷後壓力症候群之方法
WO2021064589A1 (en) * 2019-09-30 2021-04-08 Cadila Healthcare Limited Intranasal pharmaceutical compositions of cyclobenzaprine
JP2023521167A (ja) 2020-04-08 2023-05-23 トニックス ファーマシューティカルズ ホールディング コーポレーション 性機能障害のシクロベンザプリン処置
JP2023554597A (ja) 2020-11-20 2023-12-28 トニックス ファーマシューティカルズ ホールディング コーポレイション アルコール使用障害のためのシクロベンザプリン処置
US20240024256A1 (en) 2020-12-07 2024-01-25 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for fibromyalgia
WO2022170107A2 (en) 2021-02-04 2022-08-11 Tonix Pharmaceuticals Holding Corp. An improved method of assessing clinical response in the treatment of ptsd symptoms
WO2023059728A1 (en) 2021-10-06 2023-04-13 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine for treatment or prevention of sexual dysfunction associated with mental health conditions in female patients
WO2023250036A1 (en) 2022-06-21 2023-12-28 Tonix Pharmaceuticals Holding Corp. Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
WO1999018937A1 (en) * 1997-10-16 1999-04-22 Merck & Co., Inc. New cyclobenzaprine composition
PT1077683E (pt) * 1998-05-14 2003-04-30 Alza Corp Terapia anti-depressiva
WO2001012175A1 (en) 1999-08-13 2001-02-22 Vela Pharmaceuticals Inc. Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine
US6358944B1 (en) 1999-08-13 2002-03-19 Vela Pharmaceuticals, Inc. Methods and compositions for treating generalized anxiety disorder
WO2001089476A1 (en) * 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
WO2002094229A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of muscle relaxants through an inhalation route
EP1596824A4 (en) * 2003-02-04 2011-11-23 Chrysalis Tech Inc AEROSOL FORMULATIONS AND AEROSOL DISTRIBUTION OF BUSPIRONE, BUPRENORPHINE, TRIAZOLAM, CYCLOBENZAPRINE AND ZOLPIDEM
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US20090148532A1 (en) * 2007-12-06 2009-06-11 Venkatesh Gopi M Preparation of controlled release skeletal muscle relaxant dosage forms
JP2009079060A (ja) * 2008-10-15 2009-04-16 Novadel Pharma Inc 極性または非極性の、バッカルスプレーまたはカプセル
US20100266682A1 (en) * 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
LT2501234T (lt) * 2009-11-20 2017-12-11 Tonix Pharma Holdings Limited Būdai ir kompozicijos, skirti simptomų, susijusių su potrauminiu streso sutrikimu, gydymui naudojant ciklobenzapriną
US20110319389A1 (en) * 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
ITMI20110558A1 (it) * 2011-04-06 2012-10-07 Campiglio Consulting Srl Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
PT2968992T (pt) * 2013-03-15 2020-02-18 Tonix Pharma Holdings Ltd Formulações eutécticas de cloridrato de ciclobenzaprina e manitol

Also Published As

Publication number Publication date
DK2861223T3 (da) 2022-11-07
CN104684550A (zh) 2015-06-03
NZ726488A (en) 2018-10-26
US20140171515A1 (en) 2014-06-19
PT2861223T (pt) 2022-11-07
TW201408281A (zh) 2014-03-01
EP2861223B1 (en) 2022-08-03
WO2013188847A8 (en) 2015-02-05
JP6259452B2 (ja) 2018-01-10
IL236268A0 (en) 2015-02-26
ZA201500288B (en) 2022-05-25
WO2013188847A1 (en) 2013-12-19
RS63822B1 (sr) 2023-01-31
AU2013274003B2 (en) 2018-07-05
HK1209361A1 (en) 2016-04-01
HRP20221325T1 (hr) 2022-12-23
IL236268B (en) 2022-03-01
CA3118913A1 (en) 2013-12-19
MX2014015436A (es) 2015-07-14
MY194495A (en) 2022-11-30
SG11201408318RA (en) 2015-01-29
SG10201605407TA (en) 2016-08-30
CA2876902C (en) 2021-07-13
JP2021138765A (ja) 2021-09-16
EP2861223A1 (en) 2015-04-22
TW201731494A (zh) 2017-09-16
TWI683660B (zh) 2020-02-01
AU2013274003A1 (en) 2015-02-05
TWI590820B (zh) 2017-07-11
AR092330A1 (es) 2015-04-15
TWI642429B (zh) 2018-12-01
CA3118913C (en) 2024-04-30
BR112014031394B1 (pt) 2022-10-18
EP2861223A4 (en) 2016-01-27
JP2024032964A (ja) 2024-03-12
NZ631144A (en) 2016-12-23
JP2019123757A (ja) 2019-07-25
AU2018241128A1 (en) 2018-10-25
TW201842903A (zh) 2018-12-16
BR112014031394A2 (pt) 2017-06-27
LT2861223T (lt) 2022-12-12
PL2861223T3 (pl) 2022-12-12
CA2876902A1 (en) 2013-12-19
CN111388430A (zh) 2020-07-10
JP2015519404A (ja) 2015-07-09
AU2018241128B2 (en) 2020-05-21
BR112014031394A8 (pt) 2021-11-03
MX2021005317A (es) 2022-12-16
HUE060175T2 (hu) 2023-02-28
SI2861223T1 (sl) 2023-01-31
JP2017222726A (ja) 2017-12-21

Similar Documents

Publication Publication Date Title
ES2929133T3 (es) Composiciones y métodos para la absorción transmucosa
US11737991B2 (en) Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride
US20150290211A1 (en) Pharmaceutical compositions
US20180228797A1 (en) Pharmaceutical compositions
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
US20230077183A1 (en) Oral administration of ketamine
US20050089558A1 (en) Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
WO2014145045A1 (en) Compositions and methods for transmucosal absorption